Supplementary Table 1 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Authors
Thomas H. A. Ederveen (ORCID: https://orcid.org/0000-0003-0068-1275)
Kalijn F. Bol (ORCID: https://orcid.org/0000-0003-4165-2040)
Supplementary Table 1 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Thomas H. A. Ederveen, Kalijn F. Bol, Uta Flucke, Stefan G. van Ravensteijn et al.
Topics
Vascular Tumors and Angiosarcomas
article
Supplementary Table 1 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Thomas H. A. Ederveen, Kalijn F. Bol, Uta Flucke, Stefan G. van Ravensteijn, Tessa J.J. de Bitter, Mark A.J. Gorris, Yvonne M.H. Versleijen‐Jonkers, Jacco J. de Haan, Suzanne E. J. Kaal, Melissa H.S. Hillebrandt-Roeffen, Hans A. J. Gelderblom, Carla M.L. van Herpen, Ingrid M.E. Desar, Annemarie Boleij, Minke Smits, Frank M. Speetjens, Maikel J.L. Nederkoorn, Han J. Bonenkamp, Alem Gusinac
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Supplementary Table 1 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses — Thomas H. A. Ederveen, Kalijn F. Bol, et al. · (2025) | TGRS Research Map | TGRS